ArticleRheumatology and therapy2026
Sex Differences in Treatment Expectations, Satisfaction and Tolerance After Switching to CT-P17, an Adalimumab Biosimilar: A Post Hoc Analysis of the YU-MATTER Study.
Article in Rheumatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05427942 (YUflyma®), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
YUflyma® (Adalimumab), Patient Experience After Switching to adaliMumab biosimilAr High concenTration, Low Volume (40mg/0.4mL) (Yuflyma®) by Taking Patient pERception of Treatment Into Account: The YU-MATTER Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionData suggest that women and men differ in how they experience biological treatment. This post hoc analysis of the YU-MATTER study evaluated sex-related differences in patient satisfaction and perception when switching from adalimumab (reference or biosimilar) to CT-P17 (Yuflyma
methodsThis analysis used data from the observational, multicentre, prospective YU-MATTER study. Patients had inflammatory bowel disease or chronic inflammatory rheumatic disease and switched from adalimumab (reference or low-concentration [< 50 mg/ml] biosimilar) to CT-P17. Patients completed online questionnaires monthly to month 3 (M3). The primary outcome was overall patient satisfaction (7-point Likert scale). Additional outcomes were expectations and perceptions of switching to CT-P17 (7- and 5-point Likert scale, respectively), beliefs about medicine (18-item Beliefs about Medicines Questionnaire), health literacy (16-item Health Literacy Survey Europe) and injection site reactions (pain and itching: 0-10 numerical rating scale; redness and haematoma: 4- and 3-point Likert scale, respectively).
resultsYU-MATTER enrolled 115 women and 117 men. More men than women reported satisfaction with CT-P17 treatment at M3 (82.1% vs 68.7%). Beliefs about medicines, health literacy, and patient expectations and perceptions of CT-P17 treatment did not differ significantly between sexes, although more women expected CT-P17 to be less painful (73.0% vs 59.0%; p = 0.077). At baseline, women reported significantly higher incidences of injection site redness (60.9% vs 48.7%) and haematoma (50.4% vs 26.5%) than men, with similar trends at M3 (40.0% vs 20.2% and 32.6% vs 8.5%, respectively), as well as significantly higher severity of injection site pain and itching. Both sexes reported fewer and less severe injection site reactions with CT-P17 at M3 compared with baseline adalimumab.
conclusionMost expectations and perceptions of CT-P17 treatment were similar between sexes, but women experienced more injection site reactions. Further research is needed to understand why women experience a higher incidence of these reactions with adalimumab and its biosimilars.
trial registrationClinicaltrials.gov identifier NCT05427942 (registered June 22, 2022).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.